Cytoprotective actions of 2,4‐dimethoxybenzylidene anabaseine in differentiated PC12 cells and septal cholinergic neurons
- 1 February 1994
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 31 (2) , 135-141
- https://doi.org/10.1002/ddr.430310208
Abstract
The potential cytoprotective actions of a novel nicotinic agent 2,4‐dimethoxybenzilidene anabaseine (DMXB) were investigated in differentiated PC12 cells and transected rat septal cholinergic neurons in vivo. In NGF‐differentiated PC12 cells, removal of both NGF and serum led to cell loss, a reduced % of cells expressing neurites, the release of lactate dehydrogenase, and a decrease in total cellular protein. Cell loss was apparent within 24 h, and remained constant between 4–8 days post‐NGF removal. NGF alone (100 ng/ml), DMXB (10 μM), but not nicotine (10 μM), prevented these cell and neurite losses. DMXB‐induced cytoprotection was blocked by 1 μM mecamylamine. DMXB (1 mg/kg, ip) injected twice but not once per day protected cholinesterase‐staining septal neurons from retrograde degeneration following unilateral fimbrial transections. The twice per day DMXB injection‐protocol also decreased cell roundness among cholinesterase‐staining cells in the lesioned septal hemisphere compared to saline‐injected animals. These studies suggest that DMXB may exert cytoprotective activity in NGF‐sensitive neuronal populations.Keywords
This publication has 21 references indexed in Scilit:
- Effects of anabaseine‐related analogs on rat brain nicotinic receptor binding and on avoidance behaviorsDrug Development Research, 1994
- Long Range Transmission of Polar Effects in Cholinergic 3-Arylideneanabaseines. Conformations Calculated by Molecular ModellingHETEROCYCLES, 1993
- Nicotinic receptors that bind α-bungarotoxin on neurons raise intracellular free ca2+Neuron, 1992
- A neuronal nicotinic acetylcholine receptor subunit (α7) is developmentally regulated and forms a homo-oligomeric channel blocked by α-BTXNeuron, 1990
- Effects of nerve growth factor on cholinergic brain neuronsTrends in Pharmacological Sciences, 1989
- Potential use of nerve growth factor to treat Alzheimer's diseaseNeurobiology of Aging, 1989
- How many kinds of nicotinic acetylcholine receptor are there?Trends in Neurosciences, 1989
- Neuronal nicotinic α-bungarotoxin sitesCanadian Journal of Physiology and Pharmacology, 1988
- Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransectionBrain Research, 1988
- Possible regulatory function of acetylcholine receptor in maintenance of retinotectal synapsesNature, 1977